Immune-stimulating effects of low-dose Larch arabinogalactan extracted from h r i x occiderttcrlis were evaluated in a Randomized, double-blind, placebo-controlled, 44veek clinical trial. Twenty-one healthy male volunteers ( 2 2 4 5 years) were randomized-to one of six treatment groups or placebo, three subjects in each group. Of these, 19 (90%) completed for inclusion in outcome analysis. Three concentration grades of Larch arabinogalactan in two doses, 1.5g/drty and 4.5g/day, were tested. White blood cell count, monocites, serum interfcron-y, Tumor Necrosis Factor-a, interleukin-6, and quality of life (SF-36) at baseline and 4 weeks. There were no changes in the objective immunologic and subjective measures of quality of life (p > 0.05) with low doses of Larch arabinogalactan. Understanding of possible low-dose responses to Larch arabinogalactan and the determination of clinically effective baseline doses for patient care requires further investigation, and future studies should consider larger cohort populations.
here are numerous nutritional and herbal dietary supplements shown to enhance the immune system (Braun et al., 2001; Currier & Miller, 2001; Dai et al., 2001;  T Vivian, Tal, ,& Inna, 2001) . Arabinogalactan extracted from the bottom 10 to 15 feet sections of harvested h r i k occiderirnlis (Western Larch tree), referred to as Larch arabinogalactan, appears to be one such immune-enhancing herbal extract currently available as a dietary supplement in the U.S. market (D' Adamo, 1990; Kelly, 1999) . Arabinogalactans are ubiquitous in plants and found in a variety of medicinal herbs cultivated all over the world, including such plants as Echirincea species (Egert & Beuscher, I992) , Bq7tisin rimtoria (Egert & Beuscher, 1992) , Cwciinia h i g a (Gonda, Tomoda, O h m , & Takada, 1993) , A~igelica acrrriloba (Kiyohara, Cyong, & Yamada, 1989) , Neriirrri iridicirrn (Dong & Fang, 2001) , 7?riospora corrlifolin (Chintalwar et al., 1999) and Snposhriikoria clii*aricatn (Shimizu et al., 1989) . Some are bound to proteins such as those found in Lycirrrn (Qin, Yamauchi, Aizawa, Inakuma, & Kato, 2001) .
Arabinogalactan is a densely strbctured polysaccharide composed of galactose and arabinose molecules in a 6: 1 ratio. The densely structured branches of high-molecular Larch arabinogalactan polysaccharides of 3, 6-beta-D-galactan (Figure 1) are found in many different fractions and molecular weights (Odonmazig, Ebringerova, Machova, & Alfoldi, 1991) . The many fractions of Larch arabinogalactan may perhaps account for its potentially wide range of biological properties and activities. For example, the two major fractions
of Larch arabinogalactan are 16,000 and 100,000 which appear to have ininiunological activities (D'Adanio, 1990) . Hence, although the same constituents make up arabinogalactans found in plants, the molecular weights and subsequent structures are highly variable which may contribute to variability in biological activities of arabinogalactans in different herbal preparations.
The antigenic regions of imniunoreactive polysaccharides such as arabinogalactans from medicinal plants are also shown to have structural differences (D'Adamo, 1990; Egert & Beuscher, 1992; Odonmazig et al., 1994) . The variability may be due to the polysaccharides functioning as antigens when binding to various cellular membrane receptors such as iniinunomodulating cells. Since the immune stimulating antigenic regions of polysaccharides are unique and structurally different, activation of the immune system may occur through different receptors on leukocytes. The specificity of receptor sites to biological markers and translation of activities triggered from binding are different depcnding on the specific markers, and arabinogalactan may function as such. For example, a recent review describes the multiple functional roles of arabinogalactan proteins in development of plants (Majewska-Sawka 8: Nothnagel, 2000) .
Current literature appears to support immune stimulating effects of Larch arabinogalactan. Lower molecular weight polysaccharides typically exhibit an anti-inflammatory, anti-complement, anti-allergy effect while those of higher weights stimulate natural killer cell (NK) cytotoxicity and reticuloendothelial cells (D'Adamo, 1990) . Larch Arabinogalactan and its varying molecular weights have been shown to increase circulating peripheral blood monocytes (Hauer & Anderer, 1993) . Tumor cells pretreated with Larch arabinogalactan have been shown to enhance NK cell cytotoxicity, phagocytic capacities of macrophages and lymphocytes, and to increase release of various cytokines such as IFN-y, TNF-a, IL-Ip, and IL-6 (Causey, 1999; Causey, Robinson, Feirtag, Fulcher, 8c Slavin, 1999) . These unpublished studies showed that when healthy donor blood samples were treated with Larch arabinogalactah (24-hour incubation), macrophage cell density, TNF-a, and IL-6 increased (Causey, 1999; Caiisey et al., 1999) .
The dense polysaccharides of Larch arabinogalactan are also considered a good source of dietary fiber, improving intestinal microflora and enhancing total favorable anaerobic bacteria population in the intestine (D' Adamo, 1990; Kelly, 1999) , including BiJidolobacteriiriii, Lncrobncillirs midopliilirs, and Eiiterobrrcterrrcea in human studies (Crociani, Alessandrini, Mucci, & Biavati, 1993; Robinson, Feirtag, 8: Slavin, 2001 ; Salyers, Arthur, & Kuritza, 198 1).
Larch arabinogalactan fibers are fermented by gastrointestinal microflora resulting in the production of short-chain fatty acids (especially butyrate and proprionate). These fatty acids are of particular value to colonocytes and are the intestinal epithelial cells preferred fuel for energy generation. Fermentable fiber has been shown to promote the growth of indigenous intestinal microflora, particularly acidogenic bacteria, and to yield large amounts of short-chain fatty acids with decreased intestinal pH which modify the environment of the gastrointestinal tract and prevent colonization by Ciosrricliian clificcile (May, Mackie, Fahey, Cremin, & Garleb, 1994) . These factors also appear to contribute to the prevention of growth and endogenous toxin production by Clostridiiriii difl7cile and other pathogenic intestinal bacteria. In addition, Larch arabinogalactan may interfere with lectin binding to the gastrointestinal mucosa, thereby decreasing hyperreactive gastrointestinal inflammatory responses to unfavorable food lectins (Kelly, 1999) .
There are numerous patents over a 35-year period (1962 to 1977) in product developments using Larch arabinogalactan. According to the Generally Recognized as Safe Notice (GRN 000017, June 6,2000) from the FDA's Center for Food Safety and Applied Nutrition, functional properties of Larch arabinogalactan permit its use as a film-former, foam adhesion, additive, thickener, bulking agent, emulsifier, and therapeutic agent. Based on food grade status and numerous studies supporting the safety of Larch arabinogalactan, it is considered to be extremely safe with minimum to no toxicity.
The immune-stimulating effects observed in previous studies using Larch arabinogalactan were tested to address the following: 1.
3.
to assess response to low dose (1.5g/day and 4.5g/day) of Larch arabinogalactan in three different concentration grades; to assess both objective and subjective outcome responses; and to assess long-tern1 (4 weeks) effects of low dose Larch arabinogalactan intenentions on liver and kidney function. In this report the clinical and laboratory findings of healthy male subjects in n randomized, double-blind, placebo-controllcd pilot study will be discussed.
RlETHOD

Participan ts
The project was approved by the Institutional Review Board of the Southwest College of Naturopathic Medicine & Health Sciences. Subject enrollment followed the selection criteria procedure accepted by the human subjects research protection board. Potential study participants were recruited using posted fliers and local advertisements. After screening over 46 potential candidates, 21 subjects were qualified to participate (Table 1) . The subjects were screened by the same investigators of the project in order to ensure consistent, proper selection. Subjects with chronic diseases,.acute illness at start of study, and those taking any known immune-enhancing or altering supplements or medication were excluded from the study. Evaluation of subjects included detailed medical history and their use of alternative medicine including botanicals, nutritional supplements, homeopathy, neutraceutical products, and acupuncture.
The selected healthy male subjects were randomly assigned to one of the six treatment groups or placebo. All subjects were followed at the Southwest Naturopathic Medical Center in Scottsdale, Arizona. Before enrollment, each subject provided voluntary, written, informed consent to participate. A total of 19 subjects completed the study; two subjects (10%) failed to return for follow-up visits and lab tests. The two patients' non-compliance was unrelated to difficulties in taking the pills, tolerability, or adverse reactions from the botanicals. Subject compliance to study requirements during the 4week intervention was monitored by phone call follow-ups at two weeks into the study.
Intervention Protocol
The quality assurance of Larch arabinogalactan source including identity, purity and consistency of content, amount per capsule, and contaminant testing (bacteria, yeast, mold, and heavy metals) were provided by the manufacturer of the dietary supplement. The manufacturer follows the standards of the Dietary Supplement Health and Education Act of 1994 and the current Good Manufacturing Practices conditions. The project was completed within the date of expiration, and the Larch arabinogalactan used in the study was prepared from the same batch. Analytical chemistry procedure included high-performance liquid chromatography for the qualitative and quantitative profiles for Larch arabinogalactan. The , (1/3) . The experimental supplements and placebo were indistinguishable in size, color, and taste.
Outcomes Analysis
The effects of the investigational supplements on the subjects' health and immune function were assessed with laboratory tests and subjective reportings of quality of life. Blood and stool samples were collected at the beginning (baseline) and at end of four weeks (end of treatment Ware, Lu, & Sherbourne, 1993; McHorney, Ware, & Raczek, 1994; Ware & Sherbourne, 1992) . These instruments were self-administered by subjects at baseline and at four weeks. The SF-36 was chosen for its rnulti-dimensionality, brevity, and previous, successful application in the study of a variety of diseases (Brazier et al., 1992; Katz, Larson, Phillips, Fossel, & Liang, 1992) . Reponses to the 36 items are considered to assess a number of QoL domains. These domains range from those reflecting predominantly social and emotional well-being including overall sense of vitality, ability to function in social roles, ability to perform expected emotional and social roles, and overall sense of mental health. The SF-36 scores range from 0 (lowest) to 100 (highest), with higher scores indicating better QoL. To assess the QoL effect of the investigational substance in the subjects, baseline SF-36 were cornpared with the values after the 4-week intervention and placebo group.
Statistical Analysis
Using the Statistical Analysis System, we used a Student's t-test, Wilcoxon's signed-rank test, and Signed test to assess differences between baseline and after treatment. The hematologic and immunologic lab values and QoL scores in the subjects taking the six investigational substances were compared with the placebo-treated group.
RESULTS
Hematologic and Ininiunologic Studies
There were no significant changes in hematology, red blood cell, hematocrit, hemoglobin, total white blood cell, and monocytes between baseline and 4-week in the study groups ( J I > 0.05) ( Table 2) . Immunologic responses, serum IFN-y, TNF-a, and IL-6 had no statistical significant differences at end of treatment 0, > 0.05). The lab results of liver and kidney function showed no adverse changes. The Grade 1000 4.5glday group had only one outcome analysis from one subject completing the study, and the results were shown to be statistically insignificant.
Intestinal Anaerobe Cultures
Intestinal anaerobe bacterial stool cultures for Lacfobacillris acidophilirs and Eiiterobacferacea and total anaerobe reported as colony-forming units showed no significant results 0, > 0.05).
Quality of Health Assessment
SF-36 measuring QoL showed no significant changes in any of the eight domains of health: physical function, role physical, bodily pain, general health, vitality, social function, role emotion, and mental health (P>0.05). The total score changes did not improve in any of the six treatment groups between baseline and 4-week and when compared to the placebo group (P>0.05).
Adverse Reactions
There was no complaint of any physical discomfort, difficulties in pill taking, or side effects reported by the subjects during the 4-week therapy.
DISCUSSION
In the current study, based on the small population group used in the research, the immunomodulating markers, microflora population, and QoL results are inconclusive, and the research merits further investigation using a clinically significant test group in order to render conclusive outcomes. There appears to be a lack of biological activity with low-dose Larch arabinogalactan in the cohort healthy male volunteers. The results likely arise from flaws in our methodology (insufficient sample size or inadequate length of therapy) rather than the ineffectiveness of the therapy. The effects of Larch arabinogalactan on immunomodulation and benefits to intestinal microflora found in previous studies may not be apparent with relatively low doses of Larch arabinogalactan. In conditions affecting the immune system and gastrointestinal microflora such as chronic infections or intestinal dysbiosis (increased intestinal permeability), the results may have differed; hence, such conditions may be appropriate for future studies. This study suggests the safety of low-dose Larch arabinogalactan from Lnri-r occidentalk in a healthy male population and has raised some questions for further exploration of the effects of Larch arabinogalactan. Future pharmacokinetics and pharmacodynamics studies including bioavailability tests at varying doses will provide insight to understand and determine the clinically effective doses of Larch arabinogalactan to induce positive improvements in the intestinal microflora and immune-enhancing actions. Research studying the specific (active) and non-specific (innate) immune system should be explored to understand the mechanisms involved in the antimicrobial and anti-inflammatory effects reported in clinical outcomes in patient care testimonials (D' Adamo, 1990; Kelly, 1999) . High dose studies designed to assess immediate response (<lo days of treatment) of the immune system in healthy subjects and in acutely ill patients may provide more indepth understanding of how Larch arabinogalactan dietary supplement enhances the immune system. A double-blind, placebo-controlled crossover trial utilizing the highest therapeutic dose and treatment intervention period of the Larch arabinogalactan should also bc planned for the future.
